(Q24685557)

English

Structural reengineering of imatinib to decrease cardiac risk in cancer therapy

scientific article

In more languages

default values for all languages

No label defined

No description defined

edit

Statements

instance of

scholarly article

0 references

title

Structural reengineering of imatinib to decrease cardiac risk in cancer therapy (English)

0 references

1 reference

1

George D Demetri

0 references

language of work or name

English

0 references

publication date

December 2007

0 references

published in

Journal of Clinical Investigation

0 references

volume

117

0 references

issue

12

0 references

page(s)

3650-3

0 references

cites work

Major response to imatinib mesylate in KIT-mutated melanoma.

1 reference

stated in

PubMed Central

reference URL

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2096446

retrieved

7 April 2017

Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial

1 reference

stated in

PubMed Central

reference URL

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2096446

retrieved

7 April 2017

Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias

1 reference

stated in

PubMed Central

reference URL

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2096446

retrieved

7 April 2017

Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia

1 reference

stated in

PubMed Central

reference URL

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2096446

retrieved

7 April 2017

Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors

1 reference

stated in

PubMed Central

reference URL

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2096446

retrieved

7 April 2017

An anticancer C-Kit kinase inhibitor is reengineered to make it more active and less cardiotoxic

1 reference

stated in

PubMed Central

reference URL

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2096446

retrieved

28 September 2017

Molecular mechanisms of cardiotoxicity of tyrosine kinase inhibition

1 reference

stated in

PubMed Central

reference URL

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2096446

retrieved

28 September 2017

PDGF receptors as targets in tumor treatment

1 reference

stated in

PubMed Central

reference URL

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2096446

retrieved

28 September 2017

Cardiotoxicity of the cancer therapeutic agent imatinib mesylate.

1 reference

stated in

PubMed Central

reference URL

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2096446

retrieved

28 September 2017

Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial

1 reference

stated in

PubMed Central

reference URL

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2096446

retrieved

28 September 2017

Tyrosine kinases as targets for cancer therapy

1 reference

stated in

PubMed Central

reference URL

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2096446

retrieved

28 September 2017

Glivec (STI571, imatinib), a rationally developed, targeted anticancer drug

1 reference

stated in

PubMed Central

reference URL

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2096446

retrieved

28 September 2017

Imatinib does not induce cardiac left ventricular failure in gastrointestinal stromal tumours patients: Analyis of EORTC-ISG-AGITG study 62005

1 reference

stated in

PubMed Central

reference URL

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2096446

retrieved

28 November 2018

Clonal evolution of resistance to imatinib in patients with metastatic gastrointestinal stromal tumors

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/18060025

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

0 references

0 references

PubMed publication ID

18060025

0 references

(Q24685557)

Structural reengineering of imatinib to decrease cardiac risk in cancer therapy

Statements

Identifiers

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)